Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic NK cells + azacitidine
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This investigational combination therapy, developed by The Second Hospital of Shandong University, consists of allogeneic natural killer (NK) cell transfusions administered in conjunction with the hypomethylating agent azacitidine. It is currently being evaluated in a Phase 1/2 clinical trial for the treatment of patients with refractory myelodysplastic syndrome with excess blasts (MDS-EB). The therapeutic approach involves a conditioning regimen of cyclophosphamide followed by azacitidine and the infusion of donor-derived NK cells. NK cells are innate immune cells that can recognize and eliminate malignant cells through various activating receptors, while azacitidine functions as a DNA methyltransferase inhibitor, potentially sensitizing the blasts to immune-mediated destruction and reducing the leukemic burden.
- Other names
- allogeneic NK cell transfusion combined with azacitidine therapy
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)NKG2DL (NKG2D ligand family)NCR2 (Natural cytotoxicity triggering receptor 2)
Beyond the preview
Go deeper on allogeneic NK cells + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic NK cells + azacitidine.